Anavex Life Sciences Corp. (NASDAQ:$AVXL) is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer’s disease, other central nervous systems (CNS) diseases, pain and various types of cancer.

This past weekend, the company presented new clinical pharmacokinetic and pharmacodynamic data for ANAVEX2-73, at the 2017 Clinical Trials on Alzheimer’s Disease Meeting.

Specifically, data presented include new results from the Phase 1 study, the Phase 2a study, and data from the first year of the Phase 2a long-term extension study.

At 109 weeks and halfway into the long-term extension Phase 2a study, data from the cohort of patients with the higher medical concentrations point towards the continued ability of the medication to stop the decline in the exploratory secondary endpoints cognition and function. Similarly, at 57 weeks, this cohort had demonstrated improvement of the measures MMSE and ADCS-ADL compared to baseline.

CEO of Anavex, Christopher Missling said, “We are cautiously optimistic about the promising results of ANAVEX2-73 observed in patients who have received the drug for over two years. We are committed to advancing ANAVEX2-73, utilizing all relevant scientific knowledge we can learn, in hopes of helping those affected by the disease.”

Featured Image: Depositphotos/© pressmaster